FDA Shuts Down Emergency Use for Major COVID Antibody Drugs
Published Date: 7/29/2025
Notice
Summary
The FDA has officially ended the emergency use of several COVID-19 antibody treatments from Regeneron, GSK, Lilly, and AstraZeneca as of December 13, 2024. This means these drugs can no longer be used under emergency rules, affecting patients and healthcare providers relying on them. The change reflects updated safety and effectiveness info, so folks should look for other treatment options moving forward.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
EUA Revoked for Four COVID Antibodies
On December 13, 2024, the FDA revoked the Emergency Use Authorizations for REGEN-COV (casirivimab and imdevimab), sotrovimab, bebtelovimab, and EVUSHELD (tixagevimab co-packaged with cilgavimab). This means these drugs can no longer be used under emergency rules and may affect patients and health care providers who relied on them.
Revocations Cited Safety/Effectiveness; Find Alternatives
The FDA said the revocations reflect updated safety and effectiveness information and advises people who used or would have used these treatments to look for other treatment options going forward. The revocations took effect December 13, 2024.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in